Oppenheimer trimmed KLA’s price target from $850 to $700, joining a chorus of analysts adjusting expectations in the ...

Analysts are playing financial ping-pong with The Cigna Group’s price target, but the net effect is positive. Truist ...

Analysts can't seem to agree on Marsh & McLennan's stock direction, but one thing's clear—it’s making headlines. Keefe, ...

Southwest Airlines is bracing for rough skies after financial turbulence and waning consumer demand forced a hard pivot. The ...

Christopher D’Ambrosio, a corporate VP at ADP, sold 478 shares for $140,120 while the stock hovered near a 52-week high. This ...

Cerity Partners gave Regeneron a small but mighty vote of confidence, upping their stake by 3.3% in the fourth quarter. They ...

Truist Financial trimmed its price target from $120 to $113, but kept the "buy" label firmly in place. This move follows a ...

Bank of Nova Scotia made a sharp U-turn, slashing its Deere & Company holdings by a whopping 58.2% in Q4. This dramatic trim ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Quinn Opportunity Partners chomped down on a bigger slice of McDonald’s, boosting their holdings by a whopping 67.9% in Q4. They now own 23,500 shares worth about $6.8 million, thanks to a 9,500-share ...

Johnson & Johnson’s stock took a 2.3% dip during mid-day Wednesday trading, slipping below $150 to land around $146.56. Several analysts have responded by trimming their price targets, with Raymond ...

DA Davidson just pulled the financial equivalent of a weather forecast downgrade, trimming Oracle’s price target from $150 to $140. They cited looming economic sluggishness and predicted one or two ...